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Objective: To investigate glial, neuronal and amyloidal biomarkers in CSF samples 
from patients with different multiple sclerosis (MS) types.  
Methods: CSF levels of neurofilament light protein (NFL), total-tau (t-tau), tau 
phosphorylated at threonine 181 (p-tau), glial fibrillary acidic protein (GFAP), S-100B 
protein (S-100B), chitinase 3-like 1 protein (YKL-40), monocyte chemoattractant protein 
(MCP-1), α-cleaved soluble amyloid-precursor protein (α-sAPP), β-cleaved soluble 
amyloid-precursor protein (β-sAPP), and 38, 40 and 42 amino acid long fragments of 
amyloid β (Aβ38, Aβ40, Aβ42) were analysed in 109 clinically isolated syndrome (CIS) 
patients, 192 relapsing-remitting MS (RRMS), 6 secondary progressive MS (SPMS) 
and 17 primary progressive MS (PPMS) patients recruited between 20XX and 20YY at 
the XXX clinic. 
Results: The CSF levels of NFL were significantly higher in relapsing-remitting forms 
of MS, while GFAP levels were higher in progressive forms of MS. No significant 
differences were found for any of the biomarkers between the RRMS and CIS groups. 
YKL-40, MCP-1, S-100B, t-tau, p-tau and amyloidal cleavage proteins Aβ38, Aβ40, 
Aβ42 showed no significant differences among the different MS types. CSF levels of 
NFL and YKL-40 correlated in CIS patients while GFAP levels and YKL-40 levels 
correlated in RRMS patients. In relation to relapses, NFL levels were higher when the 
relapse period was extended to 3 month prior to lumbar puncture. By contrast, GFAP, 
MCP-1, tau proteins and amyloid-related markers showed increased levels during 
stable stages; while YKL-40 and S-100B were the less influenced by relapses. 
Conclusion: The CSF biomarker profile was similar among different types of MS, but 
NFL levels were higher in relapsing remitting forms of MS and CSF GFAP was higher 
in progressive MS (?). 
 
 
BRIEF ABSTRACT FOR JOURNAL OF NEUROIMMUNOLOGY (100 words) 
In the present study, CSF concentrations of NFL, t-tau, p-tau, GFAP, S-100B, YKL-40, 
MCP-1, α-sAPP, β-sAPP, and Aβ38, Aβ40, Aβ42 were measured in 109 clinically 
isolated syndrome (CIS) patients, 192 relapsing-remitting MS (RRMS), 6 secondary 
progressive MS (SPMS) and 17 primary progressive MS (PPMS) patients. The CSF 
levels of NFL were significantly higher in RRMS while CSF levels of GFAP were higher 
in PPMS. CSF levels of NFL and YKL-40 correlated in CIS patients while GFAP levels 
and YKL-40 levels correlated in RRMS patients. 
 
INTRODUCTION 
Multiple sclerosis (MS) is classically described as a demyelinating disease of the 
central nervous system (CNS) due to the histological findings of white matter lesions in 
MS brains. However, there is evidence that not only myelin and oligodendrocytes are 
implied in MS pathogenesis, but also neuronal damage and astroglial activation which 
are important features in the pathogenesis of MS [1-4]. Clinically, MS is considered a 
chronic autoimmune condition. Even though, the involvement of immune system has 
been thoroughly described in MS, there is also evidence that diffuse neurodegenerative 
processes are implied in the MS pathogenesis from the early stages of the disease [5]. 
Probably, the predominance of autoimmune activation at the onset of the disease 
explains the inflammatory course of the relapsing-remitting forms of MS. While the 
predominance of neuronal and glial degeneration would be associated with progressive 
forms of MS. Ideally, knowing the underlying histopathological process in each MS 
patient could lead to an individual treatment for a specific target. Notwithstanding, it is 
not feasible to obtain brain biopsies. Thus, MS patients are classified by their clinical 
course as clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), 
secondary progressive MS (SPMS) and primary progressive MS (PPMS), and they are 
treated according to the international standards.  
Cerebrospinal fluid (CSF) is the closest body fluid to brain tissue (ref: Blennow K et al., 
Nat Rev Neurol 2010). Therefore, CSF from a diagnostic lumbar puncture could reflect 
the features of brain damage at MS onset and could differentiate the different patterns 
of MS. 
The purpose of the present study was to investigate glial and neuronal biomarkers in 
CSF samples from patients with different MS types and to test whether a correlation 
among the biomarkers exists and whether the profile of CSF biomarkers varies among 
the different MS types. Hence, we analysed biomarkers related to axonal damage 
(neurofilament light protein: NFL) [3], neuronal injury (total-tau: t-tau and tau 
phosphorylated at threonine 181: p-tau) [6], glial activation (human chitinase 3-like 1 
protein: YKL-40 and monocyte chemoattractant protein: MCP-1) [2,7], astrocytic 
damage  (glial fibrillary acidic protein: GFAP and S-100B protein: S-100B) [1,8], and 
amyloid metabolism (α-cleaved soluble amyloid-precursor protein: α-sAPP; β-cleaved 
soluble amyloid-precursor protein: β-sAPP; 38, 40 and 42 amino acid long fragments of 
amyloid β: Aβ38, Aβ40, Aβ42) [9,10]. 
MATERIALS AND METHODS 
Patients and clinical assessments 
The present observational study was approved by the ethics committee of Bellvitge 
University Hospital, L’Hospitalet de Llobregat, Spain and informed consent was 
obtained from all patients. Samples were obtained from the Bellvitge Biomedical 
Research Institute (IDIBELL), the CSF biobank MS Unit collection. Samples were 
matched with clinical data from patients recruited and prospectively followed at the MS 
Unit, Bellvitge University Hospital. All clinical data were entered into the European 
Database for Multiple Sclerosis (EDMUS) [11]. Patients were diagnosed according to 
the Poser and McDonald criteria as appropriate and were classified as having CIS, 
RRMS, SPMS or PPMS according to the disease course when the lumbar puncture 
was performed [12-14]. For the inclusion into the relapsing group, the first signs of 
relapse had to start within one month of sampling. The neurological deficits were 
scored with the Expanded Disability Status Scale (EDSS) [15].  
 
CSF sampling and biochemical analyses 
CSF samples were collected in 109 CIS patients, 192 RRMS patients, 6 SPMS patients 
and 17 PPMS patients by lumbar puncture into polypropylene tubes, centrifuged at 
2200 x g for 10 min, aliquoted into 1 mL cryo tubes that were stored at -80oC pending 
analyses. Concentrations of CSF biomarkers were analysed in blind fashion at the 
Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, 
University of Gothenburg, using enzyme-linked immunosorbent assays as described 
[16].  
 
Statistics 
Continuous variables were described by their mean and standard deviation or median 
and interquartile range, depending on their distribution, and categorical variables by 
numbers and percentages. Differences between groups were analysed with Kruskal-
Wallis test followed by pairwise post hoc comparisons using the Mann-Whitney U test, 
p values ≤ 0.05 were considered significant. Spearman’s test was used to analyse 
correlations between demographics and CSF biomarker levels, p values ≤ 0.05 were 
considered significant. Correlations among different biomarkers were analysed using 
Spearman’s test and p values were adjusted using Bonferroni (Holms) correction (p*). 
Univariate statistical analyses were prepared using Statistical Package for the Social 
Sciences 20.0 (SPSS Inc, Chicago, IL). Multivariate analysis was performed using 
orthogonal projection to latent structures discriminant analysis (OPLS-DA) 
implemented in the software SIMCA-P+ v. 12 (Umetrics, Umea, Sweden) [17]. 
RESULTS 
Demographics and clinical characteristics of MS patients are shown in Table 1.  
CSF biomarker levels and demographics 
The correlation between age at lumbar puncture and CSF biomarker levels was 
evaluated in a total of 324 patients. Spearman’s test correlation index: NFL: - 0.21, p < 
0.0001; GFAP: 0.24, p < 0.0001; YKL-40: 0.16, p = 0.004; S-100B: 0.14, p = 0.01; p-
tau: 0.15, p = 0.007; α-sAPP: 0.16, p = 0.004, β-sAPP: 0.15, p = 0.005; no significant 
correlation was found for any other biomarker. Similar correlations were found in the 
subgroup of CIS and RRMS patients (n = 301) (Spearman’s test correlation index: 
NFL: - 0.16, p = 0.003; GFAP: 0.21, p < 0.0001; YKL-40: 0.14, p = 0.02; S-100B: 0.15, 
p = 0.01; p-tau: 0.14, p = 0.02; α-sAPP: 0.12, p = 0.04, β-sAPP: 0.12, p = 0.03). In 
relation to gender, significantly higher CSF levels of MCP-1, YKL-40, GFAP, p-tau, α-
sAPP, β-sAPP, Aβ38, Aβ40, Aβ42 were found in males vs females (Table 2). The 
subgroup of relapsing-remitting patients (n = 301) showed similar data except for YKL-
40 (males: 105 ng/mL (80-165); females 94 ng/mL (67-146), p = 0.04) and GFAP (no 
significant differences in CSF levels between males and females). There were no 
significant correlations between the EDSS at lumbar puncture time and CSF biomarker 
levels except for YKL (CI: 0.17, p = 0.002); α-sAPP (CI: -0.15, p = 0.006) and β-sAPP 
(CI: -0.14, p = 0.01). Similar correlations for EDSS were found in the subgroup of 
relapsing-remitting patients.  
CSF biomarker levels in different MS patients 
Table 2 shows the CSF biomarker levels for each group of MS patients. NFL levels 
were significantly higher in relapsing-remitting forms, while GFAP levels were 
significantly higher in progressive forms (Table 2). YKL-40 levels were higher in the 
PPMS group compared to the CIS group (Table 2).  
CSF biomarker levels and relapses. 
Patients from CIS and RRMS groups were evaluated together (n = 301) and were 
classified to be in the relapsing or remitting phase. CSF levels of GFAP, MCP-1, t-tau, 
p-tau, α-sAPP, β-sAPP, Aβ38, Aβ40, Aβ42 were significantly lower during relapse vs 
remission (Table 2). There were no differences in YKL-40 and S-100B levels between 
the relapsing and remitting stages (Table 2). CSF NFL levels were significantly 
increased only when the relapse period was extended to three months prior to 
sampling (relapse: 1455 ng/L, 677 – 2670; remission: 830 ng/L, 520 – 1835; p = 
0.009). Hence, the difference in CSF biomarker levels between the relapsing and 
remitting phase was larger for GFAP, MCP-1 and NFL, while smaller for YKL-40 
(Figure 1). Patients of the CIS group were classified depending on their first 
neurological relapse: long tracts, brainstem, spinal cord and optic neuritis. No 
association was found between biomarker levels and the type of clinical presentation at 
the time of first relapse (data not shown). 
Correlations among glial markers 
In RRMS and CIS patients, significant correlations were observed between GFAP and 
YKL-40 (CI = 0.52, p = 0.006*), between GFAP and MCP-1 (CI = 0.46, p = 0.006*) and 
GFAP and S-100B (CI = 0.31, p = 0.006*). In progressive forms of MS no correlation 
among glial biomarkers was found.  
Correlations among neuronal markers 
There was a weak but significant correlation between NFL ant t-tau (CI = 0.26, p = 
0.006*), while no correlation was found between NFL and p-tau (CI = 0.03, p = 0.57 
before Bonferroni correction). P-tau and t-tau had a strong correlation (CI = 0.77, p = 
0.004*). 
Correlations between glial and neuronal markers 
Significant correlations were observed between YKL-40 and NFL, the strongest 
correlation in the CIS group (CI = 0.59, p = 0.006*). GFAP correlated weakly but 
significantly with NFL in RRMS (CI 0.25, p = 0.006*) while no other correlation between 
GFAP and NFL was found after Bonferroni correction. No correlations were found 
between MCP-1 and NFL. In relapsing-remitting forms of MS, t-tau and p-tau 
significantly correlated with GFAP (t-tau: CI = 0.49, p = 0.005*; p-tau: CI = 0.42, p = 
0.005*) and MCP-1 (t-tau: CI = 0.31, p = 0.005*; p-tau: CI = 0.28, p = 0.005*), while no 
significant correlations were found after Bonferroni correction between t-tau or p-tau 
and YKL-40. In PPMS patients, no correlations were found between GFAP, YKL-40 or 
MCP-1 and NFL, while t-tau and p-tau showed a strong correlation with GFAP and 
MCP-1 (CI>0.58, p < 0.02 for all comparisons, but they were not significant after 
Bonferroni correction). 
Correlations among neuronal, glial and amyloidal biomarkers. 
No correlations were found between NFL and amyloidal metabolism biomarkers. While 
t-tau and p-tau showed strong and significant correlations with α-sAPP, β-sAPP, Aβ38, 
Aβ40 and Aβ42 (t-tau: CI > 0.45, p-tau: CI > 0.62, p = 0.004* for all correlations). No 
correlations were found between YKL-40 and amyloidal biomarkers. Furthermore, 
correlations between GFAP or MCP-1 and amyloidal markers were weak and only 
significant in the RRMS group (data not shown). Levels of α-sAPP and β-sAPP 
correlate strongly (CI = 0.93, p = 0.002*). Aβ38, Aβ40 and Aβ42 correlate strongly 
amongst themselves (CI > 0.92, p = 0.002* for all correlations) and with α-sAPP (CI > 
0.54, p = 0.002* for all correlations) and β-sAPP (CI > 0.58, p = 0.002* for all 
correlations). 
DISCUSSION 
In the present study we analysed 12 different biomarkers related to neurons, glia and 
amyloid metabolism in 324 CSF diagnostic samples of different MS types. The CSF 
biomarker profile was similar among different types of MS except for NFL, which 
showed higher levels in relapsing-remitting forms of MS, and GFAP and YKL-40 which 
showed higher levels in progressive forms of MS. These results are in agreement with 
previously published data [18,19]. The CIS and RRMS groups showed the same profile 
of biomarkers. Our cohort of CIS patients included not only patients that presented a 
first neurological episode suggestive of MS but also fulfilled MR Barkhof criteria (ref). 
We also evaluated the influence of the relapses in the CSF biomarker levels. NFL 
showed the highest levels in the relapsing group when the relapse period was 
extended to 3 months prior to lumbar puncture. This finding is in agreement with 
previous reports and could be explained because the inflammatory process, first 
provokes demyelination and after, axonal degeneration that ends with the release of 
NFL to the environment. Then, the increasing of NFL levels in the CSF happens with a 
brief delay in time from the onset of the relapse [20]. In contrast, MCP-1 showed 
increased levels in the stable stages. There is evidence that in MS lesions, MCP-1 is 
mainly expressed by reactive astrocytes and its overexpression mediates the 
recruitment of brain resident immune cell and the recruitment of infiltrating monocytes 
from the systemic bloodstream to the lesion sites as an initial mechanism of 
inflammatory response to a brain injury [21]. However, the sustained release of MCP-1 
prolongs the inflammation and provokes cytotoxicity [21]. Therefore, we could 
hypothesize that CSF levels of MCP-1 increase during the relapse period as a 
response to tissue damage and they continue increasing beyond the period of time 
considered as clinical relapse. GFAP, tau proteins and amyloidal markers also showed 
increased levels during the stable stages, probably as a product of cell death after 
severe inflammatory processes or continuous neurodegeneration as explained above. 
YKL-40 and S-100B were the biomarkers that were the least influenced by relapses as 
we previously reported [16]. Some studies have proposed the regulation of 
inflammation and the inhibition of apoptosis as the main roles of YKL-40 in 
inflammatory diseases [2, 22]. Moreover, YKL-40 seems to be involved in tissue 
remodelling [22]. Thus, the biological functions of YKL-40 could explain its continuous 
release by activated astrocytes in MS, independently of the MS stage. The influence of 
relapses on CSF biomarker levels should be confirmed in future studies, since it could 
be useful to know whether to consider the time of the lumbar puncture is important or 
not for sampling in clinical trials or MS studies. The influence of age in CSF biomarker 
levels in healthy controls and MS patients has been described with controversial 
results, probably because the influence of the disease on biomarker levels is stronger 
than the influence of the age [2, 16, 20, 23]. In the age range of our study, we observed 
weak correlations between age and the different biomarkers, being still less significant 
in relapsing-remitting forms of MS. However, neither older nor younger ages have been 
explored. Therefore, we observed a negative correlation between NFL levels and age, 
while GFAP showed a positive correlation with age. This could be explained because 
younger patients were those in the early stages of the relapsing-remitting forms of MS 
and they probably were in a more inflammatory phase of the disease, while older 
patients were those in the progressive forms of MS. In relation to gender, glial and 
amyloidal markers showed higher levels in males, however these differences were less 
significant in the relapsing-remitting group, except for MCP-1 which showed 
significantly higher levels in males. We could hypothesize that these differences could 
be related to the higher prevalence of more severe MS forms in males associated with 
a prolonged inflammation and neurodegeneration [24]. Contrary to what we expected, 
the influence of the disability rate on the CSF biomarker levels was spurious. This 
could be explained because CSF biomarker levels could reflect more accumulative 
underlying pathological processes than disability scores at a specific point in time, 
especially if the scores are focused on motor tasks as EDSS [15]. CSF samples were 
obtained close to the time of MS diagnosis. Only 11 patients (7 RRMS and 4 SPMS) 
were under treatment at the time of lumbar puncture. Although we can not exclude that 
the treatment influenced biomarker levels in SPMS group, we consider that MS 
treatment did not influence the results of the whole study. Looking at the correlations 
among different biomarkers, we have to consider that some biomarkers are products of 
axonal degeneration (NFL), astrogliosis (GFAP) or glial activation (YKL-40 and MCP-
1), products that are released into the environment and the CSF; while other markers 
like tau proteins and amyloid metabolism products aggregate and their influx to CSF is 
reduced. This could explain stronger correlations among glial markers than those 
between axonal and neuronal markers. Another factor to take into account is the size of 
the cohorts, which could explain, for instance, that no correlations were found among 
glial markers in progressive forms of MS. Nevertheless, in spite of these limitations, 
interesting correlations were found. Thus, levels of YKL-40 correlated significantly with 
NFL levels, especially in the CIS group. This finding could be explained because both 
markers are associated with early immune processes since YKL-40 is secreted by 
activated astrocytes to regulate the inflammation and NFL are a product of axonal 
degradation after demyelination. This finding is in agreement with previous studies, 
which showed that CIS patients with high levels of both NFL and YKL-40 were 
associated with a shorter time before a second relapse [16, 25]. Moreover, significant 
correlations between YKL-40 and GFAP were observed in CIS and RRMS patients, 
which were expected since YKL-40 is released by activated astrocytes and GFAP is a 
product of mature astrocyte degradation after immune responses. Furthermore, this 
finding is in agreement with our previous work which showed that high levels of both 
YKL-40 and GFAP were independent risk factors for disability progression in RRMS 
patients [16].  
In conclusion, the present study is the first that evaluates a variety of biomarkers from 
the same CSF sample from patients with different MS types and analyses 
demographic, clinical and biological data. We observed interesting results in the group 
of relapsing-remitting forms of MS, which showed higher CSF levels of NFL and a 
strong correlation between YKL-40 and NFL and between YKL-40 and GFAP. 
 
Figure1 
Title: Importance of CSF biomarkers to discriminate active relapse from stable phase 
in relapsing-remitting MS. 
Footnote: Variable importance on the projection plots. The graph shows the relative 
contribution of the biomarkers to discriminate between patients in active relapse vs. 
stable phases in the relapsing-remitting forms of MS group. The error bars represent 
95% confidence intervals.
 
 
